XML 17 R2.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Apr. 04, 2025
Jan. 03, 2025
Current assets:    
Cash and cash equivalents $ 183,752 $ 217,374
Marketable securities 847,564 893,902
Trade receivables, net 281,637 265,437
Inventory 24,853 22,388
Prepaid expenses and other current assets 58,696 68,478
Total current assets 1,396,502 1,467,579
Non-current marketable securities 619,441 637,291
Property and equipment, net 115,030 119,391
Deferred tax assets, net 419,045 420,027
Goodwill 63,684 63,684
Right-of-use assets and other non-current assets 223,545 239,718
Total assets 2,837,247 2,947,690
Current liabilities:    
Accounts payable 42,840 38,191
Accrued compensation and benefits 89,747 109,830
Accrued clinical trial liabilities 57,635 57,976
Rebates and fees due to customers 57,840 62,376
Accrued collaboration liabilities 25,489 40,384
Other current liabilities 125,551 95,012
Total current liabilities 399,102 403,769
Non-current operating lease liabilities 187,125 190,823
Other non-current liabilities 119,996 108,895
Total liabilities 706,223 703,487
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 275,033 and 281,732 at March 31, 2025, and December 31, 2024, respectively 275 282
Additional paid-in-capital 2,292,033 2,343,915
Accumulated other comprehensive income (loss) 2,010 (1,347)
Accumulated deficit (163,294) (98,647)
Total stockholders’ equity 2,131,024 2,244,203
Total liabilities and stockholders’ equity $ 2,837,247 $ 2,947,690